FDA Accepts Genentech's Supplemental New Drug Application for XOFLUZA (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications - Associated Press https://t.co/5VAI3gO1gP

FDA Accepts Genentech's Supplemental New Drug Application for XOFLUZA (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications - Associated Press https://t.co/5VAI3gO1gP

— Discovery Institute (@discoverynj) March 6, 2019

from Twitter https://twitter.com/discoverynj

March 06, 2019 at 02:49AM